Pfizer stopt met onderzoek naar medicijnen voor de ziekte van Alzheimer en de ziekte van Parkinson. De farmaceut gaat zich richten op onderzoek naar andere aandoeningen, waarmee het bedrijf meer denkt te kunnen...

Pfizer stopt onderzoek neurowetenschappen maar creëert speciaal ondernemingsfonds Pfizer heeft bekendgemaakt haar onderzoeksprogramma’s, gericht op de ziekte van Alzheimer en Parkinson, te stoppen. Daarentegen gaat...

Arvinas has managed to secure another big pharma collaboration, after it announced that Pfizer had signed a research and licensing agreement. The deal adds to previous agreements signed with MSD and Genentech, cementing...

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company’s potential blockbuster drug for spinal muscular atrophy.

Novo Nordisk today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes into other serious chronic diseases. This has been made possible through an exclusive...

Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and has made another move to further expand its influence.